TWST — Twist Bioscience Corp

Nasdaq · Health Care · Biotechnology · CIK 1581280 ·
Last close
$140.80
Market Cap
$8.83B
52W High
$145.93
52W Low
$60.60
ADV30
1,599,806
Next earnings
2026-08-03
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 118,376,000 62,454,000 -36,280,000 -35,051,000 672,437,000 117,436,000 226,698,000
Mar 2026 110,715,000 57,122,000 -38,658,000 -44,021,000 676,214,000 122,670,000 221,120,000
Dec 2025 103,698,000 53,972,000 -33,100,000 -30,507,000 638,085,000 148,591,000 181,990,000
Sep 2025 99,009,000 50,837,000 -29,934,000 -27,138,000 641,861,000 183,049,000 168,903,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-53,072,000
Investing CF
$-45,240,000
Financing CF
$13,797,000
CapEx
$-40,151,000
Dividends Paid
Buybacks
$-18,000
EPS Diluted TTM
$-2.22
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,429,157,000
Inventory
$35,162,000
Receivables
$87,581,000
ST Investments
$49,403,000
EBIT TTM
$-137,972,000
Pretax Income TTM
$-135,853,000
Interest Exp TTM
$167,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$431,798,016
EBITDA
$-115,282,000
Free Cash Flow
$-64,822,500
Enterprise Value
$8,770,956,288
Total Cash
$166,839,008
Total Debt
$108,590,000
Shares Out
62,707,424
Trailing EPS
$-2.15
Book Value
$7.11
ROE
-29.6%
ROA
-13.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Sep 2025 376,572,000 -136,259,000 -77,670,000 641,861,000 168,903,000 -47,628,000
Sep 2024 312,974,000 -175,901,000 -208,726,000 614,323,000 141,634,000 -64,094,000
Sep 2023 245,109,000 -206,903,000 -204,618,000 776,403,000 152,971,000 -142,474,000
Sep 2022 203,565,000 -249,021,000 -217,863,000 961,378,000 171,993,000 -124,385,000

TTM Snapshot

Revenues TTM
$170,177,000
NetIncome TTM
$-117,165,000
OpCashFlow TTM
$0
Assets (Latest)
$641,861,000
Forward EPS
$-0.63

Max Pain — expiry 2027-01-15

max pain strike: $85.00 · spot: $153.91 · call oi: 2,490 · put oi: 301

Peers — same industry

TickerNameMarket CapLastDaily %
IMVT Immunovant, Inc. $8.95B $43.32
QGEN QIAGEN N.V. $8.63B $41.78
PCVX Vaxcyte, Inc. $9.21B $61.87
APGE Apogee Therapeutics, Inc. $8.38B $134.79
IBRX ImmunityBio, Inc. $8.03B $7.58

News headlines (Yahoo Finance, 1h cache)

Twist Bioscience (TWST) Q3 2026 Earnings Call Transcript
2026-08-11 01:31 · Yahoo
Twist Bioscience (TWST) Is Up 26.3% After Capital Raise And Guidance Hike Amid Legal Settlement Talks - Has The Bull Case Changed?
2026-08-08 22:11 · Yahoo
Twist Bioscience Q3 Earnings Call Highlights
2026-08-03 15:02 · Yahoo
Twist Bioscience Shares Decline Following Quarterly Earnings Miss
2026-08-03 12:33 · Yahoo
Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results
2026-08-03 11:15 · Yahoo
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
2026-08-11 18:00 · Yahoo
Leerink Partners Report Names Carterra a Core Enabler of the $7B "Lab-in-the-Loop" Antibody Discovery Market
2026-07-27 12:00 · Yahoo
Revenue Growth Reinforces Twist Bioscience Corp.’s (TWST) Technology Leadership
2026-08-07 13:04 · Yahoo
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
2026-08-05 03:45 · Yahoo
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
2026-08-04 20:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.